Bemnifosbuvir Sulfate
CandidateCAS: 2241337-84-6
Sample Stock:
Bemnifosbuvir is an investigational drug under development, primarily investigated for the treatment of hepatitis C virus (HCV) infection. It belongs to the class of NS5B polymerase inhibitors, which work by inhibiting viral replication, thereby aiding in the control and management of the infection.
Related Information
Purity:98%+
Registration:GMP/DMF
Biological Profile
Associated Conditions
kidney disease·COVID-19·chronic hepatitis C virus infection·hepatitis C virus infection
Key Intermediates
5 Items| Structure | Name | CAS No. | Sample Stock | MDL No. | Details |
|---|---|---|---|---|---|
 | ((2R,3R,4R,5R)-3-(benzoyloxy)-5-bromo-4-fluoro-4-methyltetrahydrofuran-2-yl)methyl benzoate | 1199809-24-9 | - | ||
 | 6-Chloro-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-beta-D-ribofuranosyl)-9H-purin-2-amine | 1199809-26-1 | - | ||
 | (2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol | 1998705-62-6 | - | ||
 | Isopropyl 2-(((perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate, (2S)- | 1256490-52-4 | MFCD22665799 | ||
 | (2R)-2-Deoxy-2-fluoro-2-methyl-D-erythro-pentonic acid gamma-lactone 3,5-dibenzoate | 874638-80-9 | MFCD17677380 |